238 related articles for article (PubMed ID: 23320857)
21. Peri-Operative Eltrombopag or Immune Globulin for Patients with Immune Thrombocytopaenia (The Bridging ITP Trial): Methods and Rationale.
Arnold DM; Jamula E; Heddle NM; Cook RJ; Hsia C; Sholzberg M; Lin Y; Kassis J; Blostein M; Larratt L; Amini S; Schipperus M; Carruthers J; Lane SJ; Li N; Kelton JG
Thromb Haemost; 2019 Mar; 119(3):500-507. PubMed ID: 30685874
[TBL] [Abstract][Full Text] [Related]
22. [Effectiveness of perioperative administration of eltrombopag in a patient with idiopathic thrombocytopenic purpura undergoing cardiovascular surgery].
Shomura S; Katayama Y; Kusagawa H; Komada T
Kyobu Geka; 2014 Mar; 67(3):203-6. PubMed ID: 24743530
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of bone marrow reticulin in patients with chronic immune thrombocytopenia treated with eltrombopag: Data from the EXTEND study.
Brynes RK; Orazi A; Theodore D; Burgess P; Bailey CK; Thein MM; Bakshi KK
Am J Hematol; 2015 Jul; 90(7):598-601. PubMed ID: 25801698
[TBL] [Abstract][Full Text] [Related]
24. No increased risk of cataract in adult patients with primary immune thrombocytopenia treated with eltrombopag. A French nationwide nested case-control study.
Lafaurie M; Baricault B; Soler V; Cassagne M; Sailler L; Lapeyre-Mestre M; Sommet A; Moulis G
Br J Haematol; 2020 May; 189(4):e137-e140. PubMed ID: 32155284
[No Abstract] [Full Text] [Related]
25. Thrombosis of a Left Atrial Appendage Occluder After Treatment With Thrombopoietin Receptor Agonists.
Cubero-Gallego H; Romaguera R; Teruel L; Gomez-Lara J; Berdejo J; Gomez-Hospital JA; Cequier A
JACC Cardiovasc Interv; 2018 Jan; 11(2):e15-e16. PubMed ID: 29289629
[No Abstract] [Full Text] [Related]
26. Eltrombopag for chronic immune thrombocytopenia.
Tanimoto T; Fukunaga S; Hori A; Yagasaki F; Ono S
Lancet; 2011 Jun; 377(9781):1919; author reply 1919-20. PubMed ID: 21641478
[No Abstract] [Full Text] [Related]
27. Eltrombopag in systemic lupus erythematosus with antiphospholipid syndrome: thrombotic events.
Boulon C; Vircoulon M; Constans J
Lupus; 2016 Mar; 25(3):331. PubMed ID: 26405023
[No Abstract] [Full Text] [Related]
28. Dural Venous Sinus Thrombosis and Pulmonary Embolism Following Immunoglobulin Treatment in Pediatric Patient With Immune Thrombocytopenic Purpura.
Park KM; Yang EJ; Lim YT
J Pediatr Hematol Oncol; 2017 Nov; 39(8):e508-e511. PubMed ID: 29068869
[TBL] [Abstract][Full Text] [Related]
29. Eltrombopag--an oral thrombopoietin agonist.
Sharma V; Randhawa H; Sharma A; Aggarwal S
Eur Rev Med Pharmacol Sci; 2012 Jun; 16(6):743-6. PubMed ID: 22913204
[TBL] [Abstract][Full Text] [Related]
30. Spotlight on eltrombopag in treatment-refractory chronic primary immune thrombocytopenia.
Garnock-Jones KP
BioDrugs; 2011 Dec; 25(6):401-4. PubMed ID: 22050343
[TBL] [Abstract][Full Text] [Related]
31. Eltrombopag, low-dose rituximab, and dexamethasone combination as frontline treatment of newly diagnosed immune thrombocytopaenia.
Gómez-Almaguer D; Colunga-Pedraza PR; Gómez-De León A; Gutiérrez-Aguirre CH; Cantú-Rodríguez OG; Jaime-Pérez JC
Br J Haematol; 2019 Jan; 184(2):288-290. PubMed ID: 29270980
[No Abstract] [Full Text] [Related]
32. Eltrombopag for the treatment of chronic immune (idiopathic) thrombocytopenic purpura.
Dmytrijuk A; Robie-Suh K; Rieves D; Pazdur R
Oncology (Williston Park); 2009 Nov; 23(13):1171-7. PubMed ID: 20043468
[TBL] [Abstract][Full Text] [Related]
33. Management of primary immune thrombocytopenia in a real-world setting in Japan: eltrombopag versus corticosteroids.
Wong TF; Majewska R; Tomiyama Y
Int J Hematol; 2021 Aug; 114(2):152-163. PubMed ID: 33851348
[TBL] [Abstract][Full Text] [Related]
34. Eltrombopag-induced recurrent stroke in idiopathic thrombocytopenic purpura.
Maeda Y; Yamamoto D; Tamai Y
BMJ Case Rep; 2021 Mar; 14(3):. PubMed ID: 33782072
[No Abstract] [Full Text] [Related]
35. Eltrombopag-Associated Cerebral Venous Thrombosis.
Khattak T; Mitwalli MY; Ubaid A; Shoukry A; Anjum S
Am J Ther; 2021 Jan-Feb 01; 28(1):e167-e169. PubMed ID: 33369923
[No Abstract] [Full Text] [Related]
36. Modeling and Simulation Support Eltrombopag Dosing in Pediatric Patients With Immune Thrombocytopenia.
Wire MB; Li X; Zhang J; Sallas W; Aslanis V; Ouatas T
Clin Pharmacol Ther; 2018 Dec; 104(6):1199-1207. PubMed ID: 29536526
[TBL] [Abstract][Full Text] [Related]
37. Eltrombopag-associated erythromelalgia in idiopathic thrombocytopenic purpura.
Perez J; Khouri C; Park S; Imbert B; Cracowski JL
Br J Dermatol; 2022 Mar; 186(3):585-586. PubMed ID: 34698373
[No Abstract] [Full Text] [Related]
38. Eltrombopag in adult patients with immune thrombocytopenia in the real-world in France, including off-label use before 6 months of disease duration: The multicenter, prospective ELEXTRA study.
Moulis G; Germain J; Rueter M; Lafaurie M; Aroichane M; Comont T; Mahévas M; Viallard JF; Chèze S; Ebbo M; Audia S; Leclerc-Teffahi S; Sommet A; Beyne-Rauzy O; Michel M; Godeau B; Lapeyre-Mestre M;
Am J Hematol; 2022 Feb; 97(2):E40-E44. PubMed ID: 34779031
[No Abstract] [Full Text] [Related]
39. Acute kidney injury and nephrotic syndrome associated with eltrombopag therapy in chronic idiopathic thrombocytopenic purpura.
Ghosh SA; Patrick J; Maw KZ
BMJ Case Rep; 2021 Apr; 14(4):. PubMed ID: 33827880
[TBL] [Abstract][Full Text] [Related]
40. Cytomegalovirus-associated thrombocytopenia treated with thrombopoietin receptor agonist.
Simpson JD; Matthews GV; Brighton TA; Joseph JE
Intern Med J; 2016 Sep; 46(9):1096-9. PubMed ID: 27633469
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
